درمان قبلی درمان سیستمیک باعث افزایش شیوع جهش های سمی در سرطان پستان متاستاتیک شد

Systemic treatment exposure is an independent risk factor for high rates of TP53 and PIK3CA mutation, which suggests the importance of testing samples after systemic therapy to accurately assess mutations. It is worth testing the gene profile when tumours become resistant to systemic treatments.